Two Oxford Companies Think Your Genes Hold the Key to Autoimmune Disease

Their client list backs up the credibility. Genomics has maintained a partnership with Vertex Pharmaceuticals since 2018, extending it multiple times (most recently a three-year renewal in July 2024). They've also collaborated with Biogen since 2015. In February 2026, they opened a flagship London office and unveiled new AI capabilities.

Greywolf Therapeutics is the clinical-stage partner bringing the drug candidates. Founded in 2017, the company has raised nearly $100 million in Series B funding, with backers including Pfizer Ventures, ICG Life Sciences, Andera Partners, and Canaan. Their technology modulates antigen presentation (the process by which cells show protein fragments to the immune system) by inhibiting ERAP1.

Greywolf already has two programs in the clinic. GRWD5769 is in a Phase 1/2 trial for solid tumors, and GRWD0715 is in a Phase 1/2 trial for axial spondyloarthritis. The Genomics partnership is designed to expand that autoimmune footprint beyond spine disease.

Why Genetic Validation Matters More Than You Think

Drug development is brutally expensive, and most candidates fail. One of the best ways to improve your odds? Start with a target that human genetics already points to.

Genomic evidence suggests that drug targets backed by genetic data are more than twice as likely to succeed in clinical trials compared to those without such backing. That statistic, cited by Genomics, explains why pharma companies are racing to partner with genomic data platforms.

This partnership essentially functions as a de-risking exercise. Before Greywolf commits the resources to run expensive late-stage trials in multiple autoimmune diseases, Genomics can help them figure out where the genetic signal is strongest. Which patient populations? Which indications? Where is ERAP dysfunction most clearly driving disease?

As Greywolf CEO Peter Joyce put it: "Understanding the genetic drivers... is crucial to assessing which patient populations to initially focus on... to further strengthen and de-risk our pipeline."

A Much Bigger Trend Is Brewing

This deal didn't happen in a vacuum. The entire pharma industry is shifting toward genomics-driven target discovery, and the pace of dealmaking in 2026 has been staggering.

Eli Lilly inked a $1.1 billion partnership with Seamless Therapeutics in January 2026 for gene editing in genetic hearing loss. Takeda partnered with Iambic AI for small-molecule design. Illumina unveiled its Billion Cell Atlas at the J.P. Morgan Healthcare Conference, with AstraZeneca, Eli Lilly, and Merck signed on as first partners to validate genetic targets using AI at massive scale.

The common thread? Companies are no longer treating genomic data as a nice-to-have side project. It's becoming the foundation of how drugs get discovered, validated, and aimed at the right patients.

The Fine Print (and What We Don't Know)

Financial terms of the Genomics/Greywolf deal were not disclosed. No IP licensing, option rights, or commercialization agreements were announced; this is purely an R&D collaboration.

That's worth noting. This isn't a blockbuster M&A deal or a billion-dollar licensing agreement. It's two companies pooling their strengths (data on one side, drug candidates on the other) to figure out where to swing next. The real payoff, if it comes, will show up years from now when Greywolf either expands into new autoimmune indications with confidence or avoids wasting resources on the wrong ones.

The Bottom Line

The Genomics/Greywolf partnership is a quiet deal with a loud thesis: the era of guessing at drug targets is ending. Genetic data, combined with AI-powered analysis, is becoming the compass that guides where clinical dollars go.

For patients with autoimmune diseases, that matters enormously. Instead of broad immune suppression (the equivalent of carpet-bombing your own body), the next generation of treatments could be precisely targeted based on your specific genetic profile.

Greywolf's bouncer won't just be fired. He'll be retrained to do his job properly. And Genomics is handing over the employee manual.

The FDA's Biologics Gatekeeper Just Walked Out (Again)

The FDA's biologics center just lost its fifth director in a little over a year. Vinay Prasad's exit leaves CBER in limbo at a moment when gene therapies, cell therapies, and vaccines hang in the balance, and analysts are warning of months of regulatory volatility ahead.